Influence of CD4⁺/CD25⁺ regulatory T cells on atherogenesis in patients with end-stage kidney disease

References

• Meier P, Dayer E, Ronco P, Blanc E. Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end-stage renal failure. Clin. Nephrol.63(1), 8–21 (2005).
   PubMedGoogle Scholar
• Kronenberg F, Lingenhel A, Neyer U et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int.84(Suppl. 3), S113–S116 (2003).
   Google Scholar
• Meier P, Spertini F, Blanc E, Burnier M. Oxidized low-density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement. J. Am. Soc. Nephrol.18(1), 331–342 (2007).
   PubMed Web of Science ®Google Scholar
• Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int.80(Suppl. 3), S99–S102 (2002).
   Google Scholar
• Ziouzenkova O, Asatryan L, Akmal M et al. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J. Biol. Chem.274(27), 18916–18924 (1999).
   PubMed Web of Science ®Google Scholar
• Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci.92(9), 3893–3897 (1995).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Zhou X, Tornquist E, Paulsson G. The role of adaptive immunity in atherosclerosis. Ann. NY Acad. Sci.902, 53–62 (2000).
   PubMed Web of Science ®Google Scholar
• Benagiano M, Azzurri A, Ciervo A et al. T-helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl Acad. Sci.100(11), 6658–6663 (2003).
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature420(6917), 868–874 (2002).
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol.4(4), 330–336 (2003).
   PubMed Web of Science ®Google Scholar
• Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity19(2), 165–168 (2003).
   PubMed Web of Science ®Google Scholar
• Hawrylowicz CM, O’Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol.5(4), 271–283 (2005).
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat. Immunol.2(9), 816–822 (2001).
   PubMed Web of Science ®Google Scholar
• Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J. Clin. Invest.114 (9), 1209–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med.13(3), 108–116 (2007).
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science299 (5609), 1057–1061 (2003).
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 J. Exp. Med.198 (12), 1875–1886 (2003).
   PubMed Web of Science ®Google Scholar
• Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol.172 (23), 5149–5153 (2004).
   PubMed Web of Science ®Google Scholar
• Vieira PL, Christensen JR, Minaee S et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells J. Immunol.172(23), 5986–5993 (2004).
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med.203 (11), 1693–1700 (2004).
   Google Scholar
• Liu W, Putnam Al, Xu-yu Z, Szot GL et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J. Exp. Med.203 (11), 1701–1711 (2006).
   PubMed Web of Science ®Google Scholar
• Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med.188(2), 287–296 (1998).
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med.352(6), 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat. Med.8(11), 1218–1226 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol.149(2), 359–367 (1996).
   PubMed Web of Science ®Google Scholar
• Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation102(24), 2919–2922 (2000).
   PubMed Web of Science ®Google Scholar
• Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J. Intern. Med.263(5), 489–499 (2008).
   PubMed Web of Science ®Google Scholar
• Kuiper J, van Puijvelde GH, van Wanrooij EJ et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr. Opin. Lipidol.18(5), 521–526 (2007).
   PubMedGoogle Scholar
• Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc. Med.17(4), 113–118 (2007).
   PubMed Web of Science ®Google Scholar
• George J, Haratherosclerosis D, Gilburd B et al. Adoptive transfer of β(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation102(15), 1822–1827 (2000).
   PubMed Web of Science ®Google Scholar
• Mor A, Planer D, Luboshits G et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol.27(4), 893–900 (2007).
   PubMed Web of Science ®Google Scholar
• Gotsman I, Grabie N, Gupta R et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation114(12), 2047–2055 (2006).
   PubMedGoogle Scholar
• Ait-Oufella H, Salomon BL, Potteaux S et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med.12(2), 178–180 (2006).
   PubMed Web of Science ®Google Scholar
• Mor A, Luboshits G, Planer D, Keren G, Geoge J. Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes. Eur. Heart J.27(21), 2530–2537 (2006).
   PubMed Web of Science ®Google Scholar
• Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation104(7), 746–749 (2001).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation107(16), 2109–2114 (2003).
   PubMed Web of Science ®Google Scholar
• Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev.86(5), 515–581 (2006).
   PubMed Web of Science ®Google Scholar
• van Puijvelde GH, van Es T, van Wanrooij EJ et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol.27(12), 2677–2683 (2007).
   PubMed Web of Science ®Google Scholar
• Steffens S, Burger F, Pelli G et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation114(18), 1977–1984 (2006).
   PubMed Web of Science ®Google Scholar
• Taleb S, Herbin O, Ait-Oufella H et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler. Thromb. Vasc. Biol.27(12), 2691–2698 (2007).
   PubMed Web of Science ®Google Scholar
• De Rosa V, Procaccini C, Calì G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity26(2), 241–255 (2007).
   PubMed Web of Science ®Google Scholar
• Caro JF, Kolaczynski JW, Nyce MR et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet348(9021), 159–161 (1996).
   PubMed Web of Science ®Google Scholar
• Sharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int.51(6), 1980–1985 (1997).
   PubMed Web of Science ®Google Scholar
• Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int.54(4), 1267–1275 (1998).
   PubMed Web of Science ®Google Scholar
• Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J. Am. Soc. Nephrol.8(9), 1423–1430 (1997).
   PubMed Web of Science ®Google Scholar
• Bossola M, Muscaritoli M, Valenza V et al. Anorexia and serum leptin levels in hemodialysis patients. Nephron Clin. Pract.97(3), 76–82 (2004).
   Google Scholar
• Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin concentration predicts mortality in patients with chronic kidney disease stage 5 on hemodialysis therapy. Obesity15(6), 1617–1622 (2007).
   PubMed Web of Science ®Google Scholar
• Mahajan D, Wang Y, Qin X et al. CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J. Am. Soc. Nephrol.17(10), 2731–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Prichard SS. Impact of dyslipidemia in end-stage renal disease. J. Am. Soc. Nephrol.14(Suppl. 4), S315–S320 (2003).
   PubMed Web of Science ®Google Scholar
• Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J. Am. Soc. Nephrol.13(1), 204–212 (2002).
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Hellbardt S, Behrmann I et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J.14(22), 5579–5588 (1995).
   PubMed Web of Science ®Google Scholar
• Clement MV, Stamenkovic I. Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions. J. Exp. Med.180(2), 557–567 (1994).
   PubMed Web of Science ®Google Scholar
• Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol.27(5), 1207–1212 (1997).
   PubMedGoogle Scholar
• Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J. Biol. Chem.273(50), 33103–33106 (1998).
   PubMedGoogle Scholar
• Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J.14(13), 1996–2007 (2000).
   PubMed Web of Science ®Google Scholar
• Yates J, Rovis F, Mitchell P et al. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int. Immunol.19(6), 785–799 (2007).
   PubMed Web of Science ®Google Scholar
• Meier P, von Fliedner V, Markert M, van Melle G, Deppisch R, Wauters JP. One-year immunological evaluation of chronic hemodialysis in end-stage renal disease patients. Blood Purif.18(2), 128–137 (2000).
   PubMed Web of Science ®Google Scholar
• Gomez J, Martinez-A C, Gonzalez A, Garcia A, Rebollo A. The Bcl-2 gene is differentially regulated by IL-2 and IL-4: role of the transcription factor NF-AT. Oncogene17(10), 1235–1243 (1998).
   PubMedGoogle Scholar
• Lorenz HM, Hieronymus T, Grunke M, Manger B, Kalden JR. Differential role for IL-2 and IL-15 in the inhibition of apoptosis in short-term activated human lymphocytes. Scand. J. Immunol.45(6), 660–669 (1997).
   PubMedGoogle Scholar
• Maron R, Sukhova G, Faria AM et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation106(13), 1708–1715 (2002).
   PubMed Web of Science ®Google Scholar
• George J, Yacov N, Breitbart E et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with β 2-glycoprotein I. Cardiovasc. Res.62(3), 603–609 (2004).
   PubMed Web of Science ®Google Scholar
• George J, Afek A, Gilburd B, Shoenfeld Y, Harats D. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J. Am. Coll. Cardiol.38(3), 900–905 (2001).
   PubMedGoogle Scholar
• Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res.85(8), e17–e24 (1999).
   PubMed Web of Science ®Google Scholar
• Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am. J. Pathol.149(2), 675–685 (1996).
   PubMed Web of Science ®Google Scholar
• Mausner-Fainberg K, Luboshits G, Mor A et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis197(2), 829–839 (2008).
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, März W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med.353(3), 238–248 (2005).
   PubMed Web of Science ®Google Scholar